Femme et Homme
- | Pays :
- New Zealand
- Australia
- | Organes : -
- | Spécialités : -
Extrait
The study aims to assess the safety and tolerability of subcutaneous Ig NextGen 16% in patients with Primary Immune Deficiency who require Immunoglobulin (Ig) G replacement therapy. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation.
Critère d'inclusion
- Primary Immune Deficiency